Package Leaflet: Information for the User
Diltiwas Retard 120 mg prolonged-release hard capsules
diltiazem hydrochloride
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
If you have any questions, ask your doctor or pharmacist.
1. What Diltiwas Retard is and what it is used for
2. What you need to know before you start taking Diltiwas Retard
3. How to take Diltiwas Retard
4. Possible side effects
5. Storage of Diltiwas Retard
6. Contents of the pack and additional information
Diltiwas Retard is indicated for the treatment and prevention of ischemic cardiopathy.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Diltiwas Retard.
Taking Diltiwas Retard with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
In particular, do not take this medication and inform your doctor if you are taking:
Medications that contain lomitapida used for the treatment of high cholesterol levels. Diltiazem may increase the concentration of lomitapida, which may lead to an increase in the probability and severity of side effects related to the liver.
Lithium (used to treat certain mental disorders): risk of increased lithium-induced neurotoxicity.
Nitrate derivatives (used to treat hypertension):increase in hypotensive effects and dizziness (additional vasodilating effects). Inallpatients treated with Diltiwas Retard, the prescription of nitrate derivatives should only bemadein gradually increasing doses.
Theophylline (used for asthma): increase in theophylline levels in the blood.
Alpha-antagonists (used to treat hypertension):increase inanti-hypertensive effects:
The concomitant treatment withalpha-antagonists may produce or worsen hypotension.Thecombination of diltiazem with an alpha-antagonist should be considered only with strict control of blood pressure.
Amiodarone (used to decrease heart rate), digoxin (used to treat heart diseases):increase inthe risk of bradycardia (decrease in heart rate). You should be cautious when these are combined with diltiazem, particularly in elderly subjects and whenhigh doses are used.
Beta-blockers (used to treat hypertension): possibility of heart alterations.
Other antiarrhythmic agents (used to prevent or suppress heart rhythm alterations): since diltiazem has antiarrhythmic properties,it is not recommended to prescribe it concomitantly with otherantiarrhythmicagents.
Carbamazepine (used to treat epilepsy): increase in carbamazepine levels in the blood.
Rifampicin (antibiotic):risk of decrease in diltiazem levels in the blood after starting rifampicin treatment.
Agentsused to decrease stomach acid (cimetidine, ranitidine): increase in diltiazem levels in the blood.
Ciclosporin (used to suppress the immune system): increase in ciclosporin levels in the blood.
The concomitant use of Diltiwas Retard with other drugs should be carried out under medical control and adjusting the doses progressively.
Due to the possibility of additive effects,it is necessary to be cautious andcarefully evaluate patients who receive Diltiwas Retard simultaneously with other agentsthat are known to affect the heart.
Diltiwas Retard is metabolized in the liver bytheisoenzymeCYP3A4 but also inhibits it. Other drugs have a similar or opposite metabolism and there may be cases of increased levels in the blood of one or the other drug depending on whether they inhibit or not that liver enzyme.
Benzodiazepines (midazolam, triazolam used to treat anxiety): diltiazem significantly increases midazolam and triazolam levels in the blood.
Corticosteroids (methylprednisolone, used to treat inflammatory problems):diltiazem may increase the concentration of methylprednisolone in the blood and may require an adjustment of the methylprednisolone dose.
Statins:(medications to decrease cholesterol levels in the blood): diltiazem increases the concentration of some statins in the blood. There is a risk of myopathy (muscle disorder) and rhabdomyolysis (muscle necrosis with complications such as renal insufficiency) with the concomitant use of diltiazem and some statins.
Taking Diltiwas Retard with food, drinks, and alcohol
Diltiwas Retard capsules should be swallowed whole, without chewing, and with a sufficient amount of liquid, preferably before meals.
During treatment with this medication, do not take alcohol, as it may cause a
decrease in blood pressure with dizziness and/or fainting.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Do not take Diltiwas Retard if you are pregnant or think you may be, if you are planning to become pregnant, or if you are breastfeeding.
Fertile women should use an effective contraceptive method.If you become pregnant while taking Diltiwas Retard, stop taking the medication immediately and consult your doctor. Diltiwas Retard may induce fetal malformations.
Diltiwas Retard is excreted in breast milk, therefore, do not breastfeed while taking this medication.If the use ofthis medicationis considered necessary, an alternative method for infant feeding should be used.
Driving and operating machines
Based on the reported adverse reactions, that is, dizziness (frequent), general discomfort (frequent), your ability to drive and operate machines may be impaired.Therefore, it is advisable not to perform tasks that require special attention (driving vehicles, operating hazardous machinery, etc.), until the response to the medication is satisfactory.
Diltiwas Retard contains saccharose
This medication contains saccharose. If your doctor has indicated that you have an intolerance to certain sugars, consult with him before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Diltiwas Retard is administered orally. Your doctor will tell you how many capsules you should take each day.
Adults:
The dose is 1 capsule every 12 hours.Your doctor will gradually increase the dose until you obtain the optimal response.
Patients over 65 years, renal or hepatic insufficiency:
The initial dose adjustment should be done with caution.
All dose modifications and control should be done under medical supervision.
Swallow the capsules whole, without chewing, with a sufficient amount of liquid (for example, a glass of water). Diltiwas Retard should be taken preferably before meals.
Take Diltiwas Retard every day and approximately at the same time. Taking the capsules at the same time each day will have a better effect on your blood pressure. It will also help you remember when to take the capsules.
Your doctor will tell you the duration of your treatment with Diltiwas Retard. Do not stop treatment prematurely as it may be harmful to your health.
If you feel that the effect of Diltiwas Retard is too strong or too weak, consult your doctor or pharmacist.
If you take more Diltiwas Retard than you should
If you take more capsules than you should, inform your doctor or go immediately to the emergency service of a hospital. Bring the packaging of the medication with you. This is so that the doctor knows what you have taken. The following effects may occur: dizziness or weakness, blurred vision, chest pain, difficulty breathing, fainting, irregular heartbeats, difficulty speaking, confusion, decreased renal function, coma, and sudden death.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to takeDiltiwas Retard
Do not take a double dose tocompensate for the missed doses.It is essential to take Diltiwas Retard regularly at the same time each day. If you forget to take a dose, take it as soon as you can. However, if it is almost time for the next dose, do not take the missed capsule.
If you interrupt the treatment withDiltiwas Retard
If you interrupt the treatment with Diltiwas Retard, you may experience a worsening of your disease, presenting symptoms such as chest pain or a sudden increase in blood pressure. Do not stop treatment with Diltiwas Retard without consulting your doctor first.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
The side effects of diltiazem vary in intensity from one patient to another and should be taken into account especially at the beginning of treatment or when changing medication.
The following are common side effects (may affect more than 1 in 100 people):
The following are infrequent side effects(may affectup to1in 1000 people):
The following are rare side effects (may affectup to 1 in 10,000 people):
The following are very rare side effects not known (may affectup to 1 in more than 10,000 people):
The following are side effects of unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https.//www.notificaRAM.es
By reporting side effects, you can contribute to providing more information on the safety of this medication.
This medication does not require special conditions for conservation.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. In this way, you will help protect the environment.
Composition of Diltiwas Retard
Appearance of the product and contents of the packaging
Diltiwas Retard 120 mg prolonged-release hard capsules are presented in the form of hard, opaque orange and red capsules. Each package contains 40 capsules.
Holder of the marketing authorization and responsible for manufacturing
Alfasigma España, S.L.
Avenida Diagonal, 490
08006 Barcelona
Date of the last review of this leaflet: April 2023
Other sources of information
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS):http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.